Somatoform Disorders
Disorders having the presence of physical symptoms that suggest a general medical condition but that are not fully explained by another medical condition, by the direct effects of a substance, or by another mental disorder. The MEDICALLY UNEXPLAINED SYMPTOMS must cause clinically significant distress or impairment in social, occupational, or other areas of functioning. In contrast to FACTITIOUS DISORDERS and MALINGERING, the physical symptoms are not under voluntary control. (APA, DSM-V)
Subtype terms (6)
More specific conditions that are subtypes of Somatoform Disorders in the MeSH hierarchy.
- Body Dysmorphic Disorders
10 drugs (7 approved, 3 experimental)
- Body Integrity Identity Disorder
- Conversion Disorder
2 drugs (1 approved, 1 experimental)
- Factitious Disorders
- Hypochondriasis
1 drug approved
- Neurasthenia
2 drugs (1 approved, 1 experimental)
Drugs by status
Approved for this indication (6)
Phase 3 trials (1)
Phase 2 trials (2)
Organizations
Organization Involved with Phase 4 Indications (15)
- Forest Laboratories
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Washington
- Grupo Rehabilitacion en Salud
- New York University
- Northwestern University
- Universidad Autonoma de Nuevo Leon
- Universidad de Antioquia
- University of Bern
- Far Eastern Memorial Hospital
- Taipei Veteran General hospital
- Paul G. Allen Family Foundation
- Government of Taiwan
- GTO Pharmaceutical, LLC
Organization Involved with Phase 3 Indications (22)
- Grunenthal
- Ipsen
- Allergan
- National Institute of Mental Health (NIMH)
- Brown University
- Cornell University
- Harvard University
- Gottfried Wilhelm Leibniz Universität Hannover
- Rhode Island Hospital
- Justus Liebig University Giessen
- Mayo Clinic
- Hofstra University
- Aquinox Pharamceuticals Inc
- Janssen Pharmaceutica NV
- Cantonal Hospital of St. Gallen
- University of Illinois at Chicago
- New York Presbyterian Hospital
- Strathmann AG&Co, Hamburg, Germany
- Elgene Chemical
- Johnson and Johnson
- Government of Spain
- University of Picardie Jules Verne
Organization Involved with Phase 2 Indications (18)
- Takeda
- Celgene
- Millennium Pharmaceuticals
- Astellas
- Novartis
- Urigen
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute of Nursing Research (NINR)
- United States Army
- Aarhus University
- Rockefeller University
- McGill University
- Queen's University, Belfast
- Stanford University
- University of Kiel
- Watson Pharmaceuticals
- University of Sao Paulo
- The Cleveland Clinic
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (6)